EXPLORE THE SCIENCE
TL;DR: A 2026 systematic review in Future Science OA found early medication evidence for online behavioral addictions, but the 20 included studies were mostly small, male-heavy, and short-term. Key Findings Medication evidence stayed early: The review found sm…
Read article
TL;DR: A 2026 systematic review in Preventive Medicine Reports found limited but suggestive randomized-trial evidence that smoking-cessation medications can help Indigenous adults quit, especially when paired with supportive or culturally tailored care. Key Fi…
Read article
TL;DR: A 2026 human laboratory study in Drug and Alcohol Dependence Reports found that naltrexone/bupropion did not change whether people with binge-eating disorder started eating preferred snacks, but it reduced how many calories they ate once they began. Key…
Read article
New research provides clarity on the most effective cessation aids available. Varenicline, cytisine, and e-cigarettes help the greatest proportion of people quit long-term. Slowly tapering nicotine dose before ending treatment may also boost success rates. Bup…
Read article
Depression is highly prevalent in older adults and those with cardiovascular disease. Selective serotonin reuptake inhibitors (SSRIs) are generally safe first-line treatments, but many wonder if they’re safe for those with cardiovascular disease. Key Facts: Th…
Read article
Antidepressant medications like bupropion (Zyban) show potential to help people quit smoking long-term. However, the evidence is complex with both benefits and risks to consider carefully. Key facts: The antidepressant bupropion (brand name Zyban) aids quittin…
Read article
The novel combination drug dextromethorphan-bupropion (Auvelity) was recently approved by the FDA as an oral antidepressant that works rapidly to treat major depressive disorder in adults. This new medication represents an exciting development for depression t…
Read article